Pharma Projected to Have ACA to Thank for Growth - Assuming it Remains As-Is
This article was originally published in RPM Report
The Centers for Medicare and Medicaid’s Office of the Actuary projects that aggregate health care spending will grow modestly - then spike in 2014. That’s due to coverage expansions in the Affordable Care Act, and pharma stands to get among the biggest gains. The June report release means industry would have at least a couple weeks to enjoy the projections before they potentially no longer apply.
You may also be interested in...
After some success in enacting new regulatory and exclusivity incentives in the US over the past decade, antibiotic research advocates are urging action on the payment/reimbursement side. One start-up CEO argues that Medicare needs to rethink its approach to payment for hospital antibiotics.
US FDA will be transitioning from the ‘diversity plans’ outlined in recent guidance to the new, legislatively directed ‘diversity action plans’ by the end of 2023. The oncology group is leading the way in gathering early perspectives on industry approaches.
The US FDA is offering its first formal advice for potential approaches to develop psychedelic drugs for therapeutic indications. But it won’t be easy.